[Immunohistochemistry-based predictive biomarkers for lung cancer]

Area of Science:

• Oncology
• Pathology
• Biomarker Discovery

Background:

• Predictive biomarkers are essential for accurate lung cancer diagnosis.
• Molecular tests and immunohistochemistry are key technologies in this field.
• Immunohistochemistry assists in preselecting tumors for molecular analysis, especially for rare subtypes.

Purpose of the Study:

• To highlight the increasing importance of immunohistochemistry in lung cancer diagnosis.
• To emphasize its role in identifying predictive biomarkers for targeted therapies.
• To discuss the requirements for high-efficacy immunohistochemistry assays.

Main Methods:

• Review of current diagnostic methods in lung cancer.
• Analysis of the role of immunohistochemistry in biomarker identification.
• Discussion of assay validation and standardization.

Main Results:

• Immunohistochemistry significantly enhances lung cancer diagnostic efficacy.
• It enables definitive predictive classification for certain molecular subtypes.
• The number of immunohistochemistry-based biomarkers is growing with new therapeutic approvals.

Conclusions:

• Immunohistochemistry plays a vital and expanding role in lung cancer diagnosis and biomarker assessment.
• Careful antibody selection, protocol validation, and standardized scoring are critical for assay sensitivity.
• This technique is indispensable for personalized lung cancer treatment strategies.